147 related articles for article (PubMed ID: 32273248)
1. The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
Arora SP; Ananth S; Ketchum N; Gelfond J; Michalek J; Mahalingam D
J Geriatr Oncol; 2020 Sep; 11(7):1157-1160. PubMed ID: 32273248
[No Abstract] [Full Text] [Related]
2. Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
Chou TP; Hu JT; Hung CS; Chen HY
Clin Res Hepatol Gastroenterol; 2022; 46(6):101931. PubMed ID: 35472492
[No Abstract] [Full Text] [Related]
3. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Francini E; Bianco V
Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
[No Abstract] [Full Text] [Related]
4. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
5. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Xu L; Wang B; Ding W
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
[No Abstract] [Full Text] [Related]
6. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
8. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Marta GN; da Fonseca LG; Braghiroli MI; Moura F; Hoff PM; Sabbaga J
Clinics (Sao Paulo); 2021; 76():e2498. PubMed ID: 33503195
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Adachi T; Hiraoka A; Okazaki H; Nagamatsu K; Izumoto H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Yamago H; Iwasaki R; Suga Y; Mori K; Miyata H; Tsubouchi E; Ninomiya T; Michitaka K
Clin J Gastroenterol; 2020 Oct; 13(5):891-895. PubMed ID: 32468502
[TBL] [Abstract][Full Text] [Related]
11. Painful Rashes on the Palms and Soles.
Bhullar M; Bhullar A; Arachchi NJ
Ann Acad Med Singap; 2016 Oct; 45(10):479-480. PubMed ID: 27832225
[No Abstract] [Full Text] [Related]
12. Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Tajiri K; Nakajima T; Kawai K; Minemura M; Sugiyama T
Intern Med; 2015; 54(6):597-600. PubMed ID: 25786448
[TBL] [Abstract][Full Text] [Related]
13. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
[No Abstract] [Full Text] [Related]
14. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
[No Abstract] [Full Text] [Related]
15. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
16. Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Grieco A; Lombardo A; Biolato M
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):1001-2. PubMed ID: 23817448
[No Abstract] [Full Text] [Related]
17. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
[TBL] [Abstract][Full Text] [Related]
18. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
19. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Tong X; Xu X; Shi H; Liu S; Yang Z
PLoS One; 2015; 10(2):e0117168. PubMed ID: 25689846
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
[Next] [New Search]
